Diabetes mellitus is a major global public health concern, contributing substantially to morbidity, mortality, and healthcare expenditure [1]. Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by insulin resistance, progressive pancreatic beta-cell dysfunction, and increased hepatic glucose production, resulting in persistent hyperglycemia [2]. The primary objective of diabetes management is to achieve optimal glycemic control and minimize the risk of long-term microvascular and macrovascular complications. Metformin, a biguanide derivative, is widely used as a first-line pharmacological agent for the management of T2DM. Its historical development originated from the study of Galega officinalis, a medicinal plant traditionally used for glycemic regulation. Metformin is preferred because of its established glucose-lowering efficacy, relatively favorable safety profile, and low risk of hypoglycemia when used alone [2,3]. In addition to pharmacological treatment, dietary modification and regular physical activity remain important components of diabetes management. The primary antihyperglycemic action of metformin involves the suppression of hepatic gluconeogenesis, thereby reducing endogenous glucose production. It also improves insulin sensitivity and peripheral glucose utilization and may influence intestinal glucose handling. These effects collectively contribute to improved glycemic control and reduced insulin resistance [3,4]. In recent years, increasing attention has been directed toward the potential effects of metformin beyond glucose regulation, particularly its influence on inflammation and cardiovascular risk. Chronic hyperglycemia contributes to the development and progression of diabetic complications through several mechanisms, including oxidative stress, the formation of advanced glycation end products, activation of protein kinase C pathways, and endothelial dysfunction [5]. These processes promote vascular injury and may contribute to both microvascular and macrovascular complications. In addition, low-grade chronic inflammation is increasingly recognized as an important component of the pathophysiology of T2DM and its associated cardiovascular complications. C-reactive protein (CRP) is an acute-phase protein synthesized predominantly by hepatocytes in response to inflammatory stimuli, particularly interleukin-6. Increased circulating CRP concentrations are associated with systemic inflammation and have been investigated as a marker of cardiovascular risk. In patients with T2DM, elevated CRP levels may reflect the inflammatory state associated with insulin resistance, obesity, and metabolic dysfunction [5,6]. Furthermore, increased CRP concentrations have been associated with a higher risk of cardiovascular events, including myocardial infarction and ischemic heart disease [6]. Evidence also suggests that systemic inflammation may precede the clinical onset of diabetes, supporting a possible relationship between inflammatory processes and the development of metabolic disease [7,8]. Given the relationship between inflammation, insulin resistance, and vascular dysfunction, therapeutic interventions that improve metabolic control may also influence inflammatory markers. Oral antidiabetic agents, particularly metformin, have therefore attracted interest for their potential effects on inflammatory pathways in addition to their glucose-lowering properties [9]. Some studies have reported reductions in CRP concentrations following metformin treatment in patients with T2DM, although the magnitude and consistency of this response may vary according to baseline inflammatory status, treatment duration, glycemic improvement, and associated metabolic factors. Metformin may influence inflammatory activity through improvements in insulin sensitivity and metabolic regulation, as well as through possible effects on cellular signaling pathways involved in inflammation. A reduction in high-sensitivity C-reactive protein (hs-CRP), which detects relatively low concentrations of circulating CRP, may indicate an improvement in the low-grade inflammatory state associated with T2DM [10]. However, the extent to which changes in CRP are attributable to the direct anti-inflammatory effects of metformin rather than improvements in glycemic control and related metabolic parameters remains an important area of investigation. Therefore, the present study was designed to evaluate the effect of metformin therapy on serum C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus. By assessing changes in CRP following treatment, the study aims to contribute to a better understanding of the potential relationship between metformin therapy, systemic inflammation, and metabolic control in patients with T2DM.

Study Design and Study Setting The present study was conducted in the Department of Pharmacology, VIMS, Gajraula, Uttar Pradesh, India, to evaluate the effect of metformin therapy on serum C-reactive protein (CRP) levels in patients with newly diagnosed type 2 diabetes mellitus (T2DM). The study was conducted over a period approved by the institution, following the principles of the Declaration of Helsinki and applicable ethical guidelines. The study protocol was submitted to the Institutional Ethics Committee for review and approval before initiation. Written informed consent was obtained from all participants after explaining the objectives, procedures, potential benefits, and possible risks of the study. Participation was voluntary, and participants were informed of their right to withdraw without affecting their routine medical care. Study Population A total of 50 patients with newly diagnosed T2DM who fulfilled the eligibility criteria were included in the study. Participants of either sex were recruited. Baseline demographic information, medical history, general examination findings, and systemic examination findings were recorded in a structured case record form. Study Drug and Treatment Protocol All enrolled participants received tablet metformin 500 mg orally twice daily, with one dose in the morning and one dose in the evening, as prescribed by the treating physician. Participants were advised regarding medication adherence, dietary modification, and lifestyle measures appropriate for diabetes management. Any adverse events reported during the study period were documented and assessed. Study Procedure and Follow-up Baseline clinical and laboratory assessments were performed before the initiation of metformin therapy. Participants were followed up at three months and six months after treatment initiation. The scheduled assessments were conducted at three visits: baseline, the third month, and the sixth month. At each visit, relevant clinical information, treatment adherence, and any reported adverse events were documented. Follow-up laboratory investigations were performed to assess changes in glycemic parameters and serum inflammatory markers. Laboratory Investigations The following laboratory investigations were performed at baseline and repeated at the scheduled follow-up visits, as applicable: • Complete blood count (CBC). • Fasting blood glucose (FBS). • Postprandial blood glucose (PPBS). • Glycated hemoglobin (HbA1c). • High-sensitivity C-reactive protein (hs-CRP). • Blood urea. • Serum creatinine. Blood samples were collected and processed according to the standard operating procedures of the institutional laboratory. Serum hs-CRP levels were assessed to evaluate changes in systemic inflammation following metformin treatment. Study Outcomes The primary outcome was the change in serum hs-CRP levels from baseline to the third and sixth months of metformin therapy. The secondary outcomes included changes in fasting blood glucose, postprandial blood glucose, HbA1c, and other measured laboratory parameters during the follow-up period. Statistical Analysis The collected data were entered into a spreadsheet and analyzed using the Statistical Package for the Social Sciences (SPSS), version 16.0, as specified in the study protocol. Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages. Changes in laboratory parameters between baseline and follow-up assessments were analyzed using the paired Student's t-test when the data met the assumptions for parametric testing. Comparisons across all three time points could be performed using repeated-measures analysis of variance (ANOVA), where appropriate. A p-value of less than 0.05 was considered statistically significant.

A total of 90 patients with newly diagnosed type 2 diabetes mellitus were included in this illustrative study dataset to evaluate changes in glycemic parameters and serum high-sensitivity C-reactive protein (hs-CRP) following metformin therapy over six months. Table 1. Demographic characteristics of the study participants (n = 90) Demographic variable Number (n) Percentage (%) Age group (years) 30–39 12 13.3 40–49 24 26.7 50–59 32 35.6 60–69 22 24.4 Sex Male 42 46.7 Female 48 53.3 Total 90 100.0 The largest proportion of participants belonged to the 50–59-year age group (35.6%). Female participants constituted 53.3% of the study population. Table 2. Comparison of glycemic parameters at baseline, 3 months, and 6 months Parameter Baseline (Mean ± SD) 3 months (Mean ± SD) 6 months (Mean ± SD) Fasting blood glucose (mg/dL) 178.5 ± 28.4 139.2 ± 23.6 119.6 ± 18.7 Postprandial blood glucose (mg/dL) 267.8 ± 36.2 203.4 ± 31.5 169.8 ± 25.4 HbA1c (%) 8.4 ± 1.0 7.3 ± 0.8 6.7 ± 0.7 The illustrative data demonstrate progressive reductions in fasting blood glucose, postprandial blood glucose, and HbA1c during follow-up. Table 3. Comparison of serum hs-CRP levels following metformin therapy Study period hs-CRP (mg/L), Mean ± SD Absolute change from baseline Percentage change Baseline 5.8 ± 2.1 — — 3 months 4.6 ± 1.8 −1.2 −20.7% 6 months 3.7 ± 1.5 −2.1 −36.2% Mean hs-CRP decreased from 5.8 mg/L at baseline to 3.7 mg/L at six months, representing an illustrative reduction of 36.2%. This pattern is consistent with a reduction in the measured inflammatory marker, but statistical significance must be established using actual paired patient data. Table 4. Percentage changes in biochemical parameters after six months Parameter Baseline mean 6-month mean Absolute change Percentage change Fasting blood glucose (mg/dL) 178.5 119.6 −58.9 −33.0% Postprandial blood glucose (mg/dL) 267.8 169.8 −98.0 −36.6% HbA1c (%) 8.4 6.7 −1.7 percentage points −20.2% relative hs-CRP (mg/L) 5.8 3.7 −2.1 −36.2% In this example, hs-CRP and all three glycemic parameters declined over six months. The HbA1c reduction was 1.7 percentage points, from 8.4% to 6.7%. Table 5. Statistical analysis of changes in hs-CRP levels Comparison Mean hs-CRP difference (mg/L) Statistical method p-value Baseline vs. 3 months 1.2 Paired t-test 0.005 Baseline vs. 6 months 2.1 Paired t-test 0.005 3 months vs. 6 months 0.9 Paired t-test 0.005 Serum hs-CRP levels showed a progressive decline during the six-month follow-up period. The mean reduction was 1.2 mg/L at three months and 2.1 mg/L at six months compared with baseline. A further reduction of 0.9 mg/L was observed between three and six months. The reported p-value of 0.005 for each comparison indicates statistical significance at the 5% level, provided these values are confirmed by the actual statistical analysis.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, progressive pancreatic beta-cell dysfunction, and persistent hyperglycemia. In addition to disturbances in glucose metabolism, chronic low-grade inflammation plays an important role in the pathophysiology of T2DM and its associated cardiovascular complications. C-reactive protein (CRP) is an acute-phase protein that has been extensively investigated as a marker of systemic inflammation and cardiovascular risk. Studies by Pickup and Crook highlighted the role of inflammation in the pathogenesis of type 2 diabetes, supporting the concept that diabetes is associated with chronic inflammatory activity [11]. Metformin is widely used in the treatment of T2DM because of its established glucose-lowering efficacy, relatively favorable safety profile, and ability to improve insulin sensitivity. Its principal metabolic action involves suppression of hepatic glucose production, although its effects on cellular energy metabolism and inflammatory signaling have also attracted research interest. Bailey and Turner reviewed the clinical pharmacology of metformin and described its central role in the management of T2DM [12]. In addition to its metabolic effects, metformin may influence inflammatory pathways, although the clinical significance of these effects requires careful evaluation. CRP is synthesized predominantly by hepatocytes in response to inflammatory cytokines, particularly interleukin-6. Elevated CRP concentrations have been associated with obesity, insulin resistance, T2DM, and cardiovascular disease. Ridker discussed the importance of CRP as an inflammatory marker in cardiovascular risk assessment [13]. Similarly, Pradhan and colleagues demonstrated an association between inflammatory biomarkers and the subsequent development of type 2 diabetes in women, supporting a potential relationship between systemic inflammation and metabolic dysfunction [14]. In the present study, the primary objective was to evaluate changes in serum high-sensitivity C-reactive protein (hs-CRP) following metformin therapy in 90 patients with newly diagnosed T2DM. The earlier tables used illustrative values, with mean hs-CRP decreasing from 5.8 mg/L at baseline to 4.6 mg/L at three months and 3.7 mg/L at six months. These values are hypothetical examples, not verified observations from the study participants. Therefore, they cannot be used to claim that metformin significantly reduced hs-CRP in the actual study population. The potential anti-inflammatory effects of metformin have been investigated in relation to its influence on cellular energy regulation and inflammatory signaling. Zhou and colleagues demonstrated that metformin activates AMP-activated protein kinase (AMPK) through a mechanism involving inhibition of mitochondrial respiratory-chain complex I [15]. This finding provides a mechanistic basis for studying effects beyond glucose lowering, but it does not independently establish that metformin reduces circulating CRP in patients with T2DM. The relationship between glycemic control and inflammation is also relevant when interpreting changes in hs-CRP. Chronic hyperglycemia promotes oxidative stress, advanced glycation end-product formation, and endothelial dysfunction, all of which may contribute to vascular injury. The UK Prospective Diabetes Study (UKPDS) established the importance of improved glycemic control in reducing diabetes-related complications [16]. However, any observed change in hs-CRP during metformin treatment may reflect multiple influences, including changes in glucose levels, body weight, diet, physical activity, concurrent medications, and intercurrent infections. Therefore, the actual findings of the present study should be interpreted by comparing baseline, three-month, and six-month hs-CRP levels using appropriate statistical methods. Correlation analysis between changes in hs-CRP and HbA1c may further help assess whether improvements in glycemic control are associated with changes in systemic inflammation. A statistically significant reduction in hs-CRP would support an association between treatment and a change in the inflammatory marker, but a single-group before-and-after study cannot establish a direct causal anti-inflammatory effect of metformin. Carter and colleagues conducted a double-blind, placebo-controlled study to investigate the effects of metformin on CRP and complement factor C3 in overweight patients with T2DM. Their findings indicated that metformin reduced CRP, although it did not reduce complement factor C3 [17]. This study provides direct clinical evidence supporting the investigation of CRP as a potential marker of inflammatory changes associated with metformin treatment. Metformin is an established treatment for type 2 diabetes mellitus, primarily because of its effectiveness in improving glycemic control. Previous research has also suggested that metformin may reduce CRP levels in some patients with T2DM [17]. The present study at the Department of Pharmacology, VIMS, Gajraula, Uttar Pradesh, was designed to assess changes in serum hs-CRP levels and glycemic parameters over six months in 90 patients.

The effect of metformin on hs-CRP must be based on the actual patient data and statistical results. If a statistically significant reduction is demonstrated, the findings may support an association between metformin therapy and reduced systemic inflammation. However, a single-group before-and-after study cannot establish a direct causal effect or demonstrate a reduction in cardiovascular complications.

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047– 53. 2. Matthaei S, Greten H. Evidence that metformin ameliorates cellular insulinresistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. DiabeteMetab. 2001;17(1 Pt2):150–158. 3. Grzybowska M, Bober J, Olszewska M. Metformin –mechanisms of action and use for the treatment of type 2 diabetes mellitus. PostepyHig Med Dosw (Online). 2011;65:277–285. 4. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. DiabVasc Dis Res. 2008;5(3):157–167. 5. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2011;29:116– 122. 6. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: Role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. ExpClinEndocrinol Diabetes. 2007;115(1):38-41. 7. Freeman DJ, Norrie J, Caslake MJ, et al.;West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596– 1600. 8. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12. 9. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. DiabVasc Dis Res.2006;3(3):147-58. 10. Diabetes Prevention Program Research Group. Longterm safety, tolera-bility, and weight loss associated with metformin in the Diabetes Preven¬tion Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. 11. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241–1248. doi:10.1007/s001250051058. 12. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. 13. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–369. 14. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. 15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174. 16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. 17. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabet Med. 2005;22(9):1282–1284.